share_log

Berenberg Bank Begins Coverage on Certara (NASDAQ:CERT)

Berenberg Bank Begins Coverage on Certara (NASDAQ:CERT)

贝伦贝格银行开始在Certara上覆盖(纳斯达克:CERT)
Financial News Live ·  2022/09/11 03:31

Berenberg Bank started coverage on shares of Certara (NASDAQ:CERT – Get Rating) in a report released on Thursday, The Fly reports. The firm issued a buy rating and a $23.00 target price on the stock.

据The Fly报道,贝伦贝格银行在周四发布的一份报告中开始报道Certara(纳斯达克:CERT-GET评级)的股票。该公司对该股发布了买入评级和23.00美元的目标价。

A number of other analysts have also recently weighed in on CERT. SVB Leerink reduced their target price on shares of Certara from $29.00 to $26.00 and set an outperform rating for the company in a report on Wednesday, August 10th. Credit Suisse Group initiated coverage on shares of Certara in a report on Wednesday, August 24th. They set an outperform rating and a $22.00 target price for the company. Barclays reduced their target price on shares of Certara from $24.00 to $21.00 and set an overweight rating for the company in a report on Wednesday, August 17th. Piper Sandler reduced their target price on shares of Certara from $28.00 to $25.00 and set an overweight rating for the company in a report on Wednesday, August 10th. Finally, Morgan Stanley reduced their target price on shares of Certara from $24.00 to $20.00 and set an equal weight rating for the company in a report on Wednesday, August 24th. One investment analyst has rated the stock with a hold rating and seven have given a buy rating to the company. Based on data from MarketBeat.com, Certara currently has a consensus rating of Moderate Buy and an average target price of $26.13.

其他一些分析师最近也对CERT发表了看法。SVB Leerink在8月10日周三的一份报告中将Certara的股票目标价从29.00美元下调至26.00美元,并为该公司设定了表现优于大盘的评级。瑞士信贷集团在8月24日星期三的一份报告中启动了对Certara股票的报道。他们为该公司设定了跑赢大盘的评级和22.00美元的目标价。巴克莱在8月17日周三的一份报告中将Certara的股票目标价从24.00美元下调至21.00美元,并为该公司设定了增持评级。派珀·桑德勒在8月10日周三的一份报告中将Certara的股票目标价从28.00美元下调至25.00美元,并为该公司设定了增持评级。最后,摩根士丹利在8月24日(周三)的一份报告中将Certara的股票目标价从24.00美元下调至20.00美元,并为该公司设定了同等权重的评级。一名投资分析师对该股的评级为持有,七名分析师对该公司的评级为买入。根据MarketBeat.com的数据,Certara目前的共识评级为中等买入,平均目标价为26.13美元。

Get
到达
Certara
Certara
alerts:
警报:

Certara Price Performance

Certara性价比

CERT opened at $16.28 on Thursday. The firm has a market cap of $2.60 billion, a price-to-earnings ratio of -271.33, a price-to-earnings-growth ratio of 1.02 and a beta of 1.27. Certara has a fifty-two week low of $14.94 and a fifty-two week high of $45.48. The company's 50-day moving average price is $19.78 and its 200 day moving average price is $20.07. The company has a quick ratio of 3.51, a current ratio of 3.51 and a debt-to-equity ratio of 0.28.

周四,Cert开盘价为16.28美元。该公司市值为26亿美元,市盈率为-271.33,市盈率为1.02,贝塔系数为1.27.Certara的价格为52周低点14.94美元和52周高点45.48美元。该公司的50日移动均线价格为19.78美元,200日移动均线价格为20.07美元。该公司的速动比率为3.51,流动比率为3.51,债务权益比率为0.28。

Certara (NASDAQ:CERT – Get Rating) last posted its quarterly earnings data on Tuesday, August 9th. The company reported $0.09 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.11 by ($0.02). The company had revenue of $82.00 million during the quarter, compared to the consensus estimate of $85.46 million. Certara had a negative net margin of 3.14% and a positive return on equity of 4.26%. The company's revenue was up 17.0% on a year-over-year basis. During the same quarter last year, the business earned $0.03 earnings per share. As a group, sell-side analysts expect that Certara will post 0.28 earnings per share for the current year.
赛达拉(纳斯达克:CERT-GET Rating)上一次公布季度收益数据是在8月9日(星期二)。该公司公布本季度每股收益(EPS)为0.09美元,低于普遍预期的0.11美元(0.02美元)。该公司本季度营收为8200万美元,而市场普遍预期为8546万美元。Certara的净利润率为负3.14%,股本回报率为正4.26%。该公司的收入同比增长了17.0%。去年同一季度,该业务每股收益为0.03美元。卖方分析师预计,Certara作为一个整体,本年度每股收益将达到0.28美元。

Insiders Place Their Bets

内部人士下注

In other Certara news, Director Stephen M. Mclean purchased 20,000 shares of the business's stock in a transaction dated Friday, August 19th. The shares were acquired at an average price of $16.32 per share, for a total transaction of $326,400.00. Following the acquisition, the director now owns 42,000 shares of the company's stock, valued at $685,440. The acquisition was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this hyperlink. In other Certara news, CFO Michael Andrew Schemick acquired 25,000 shares of Certara stock in a transaction dated Wednesday, August 17th. The stock was bought at an average cost of $16.64 per share, with a total value of $416,000.00. Following the acquisition, the chief financial officer now owns 517,870 shares of the company's stock, valued at $8,617,356.80. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Stephen M. Mclean acquired 20,000 shares of Certara stock in a transaction dated Friday, August 19th. The shares were acquired at an average cost of $16.32 per share, with a total value of $326,400.00. Following the completion of the acquisition, the director now directly owns 42,000 shares in the company, valued at approximately $685,440. The disclosure for this purchase can be found here. Insiders sold a total of 6,196,893 shares of company stock worth $107,705,300 in the last quarter. 4.02% of the stock is currently owned by corporate insiders.

在Certara的其他新闻中,董事斯蒂芬·M·麦克莱恩在一笔日期为8月19日(星期五)的交易中购买了20,000股该公司的股票。这些股票是以每股16.32美元的平均价格收购的,总交易额为326,400.00美元。收购完成后,董事现在拥有42,000股该公司股票,价值685,440美元。此次收购是在提交给美国证券交易委员会(Securities&Exchange Commission)的一份文件中披露的,可以通过这个超级链接访问。在Certara的其他新闻中,首席财务官Michael Andrew Schemick在一笔日期为8月17日星期三的交易中收购了Certara股票25,000股。这只股票的平均价格为每股16.64美元,总价值为416,000.00美元。收购完成后,这位首席财务官现在拥有517,870股公司股票,价值8,617,356.80美元。这笔交易是在提交给美国证券交易委员会的一份文件中披露的,该文件可以通过这个超级链接获得。此外,在8月19日星期五的一笔交易中,董事斯蒂芬·M·麦克莱恩收购了20,000股Certara股票。这些股票是以每股16.32美元的平均成本收购的,总价值为326,400.00美元。收购完成后,董事现在直接拥有该公司42,000股,价值约685,440美元。此次收购的披露信息可在此处找到。上个季度,内部人士总共出售了6,196,893股公司股票,价值107,705,300美元。4.02%的股份目前由企业内部人士持有。

Hedge Funds Weigh In On Certara

对冲基金入股Certara

Institutional investors have recently added to or reduced their stakes in the company. EQT Fund Management S.a r.l. bought a new position in shares of Certara in the second quarter worth about $771,679,000. Clearbridge Investments LLC grew its position in shares of Certara by 58.7% during the 1st quarter. Clearbridge Investments LLC now owns 3,200,895 shares of the company's stock worth $68,755,000 after buying an additional 1,183,859 shares during the period. William Blair Investment Management LLC grew its position in shares of Certara by 23.0% during the 4th quarter. William Blair Investment Management LLC now owns 5,540,678 shares of the company's stock worth $157,466,000 after buying an additional 1,034,482 shares during the period. Granite Investment Partners LLC acquired a new position in Certara during the second quarter valued at approximately $18,944,000. Finally, Capital World Investors grew its holdings in Certara by 215.5% during the fourth quarter. Capital World Investors now owns 1,254,554 shares of the company's stock valued at $35,654,000 after purchasing an additional 856,959 shares during the period. 77.42% of the stock is owned by institutional investors.

机构投资者最近增持或减持了该公司的股份。EQT基金管理公司S.A.R.L.在第二季度购买了Certara的新股票头寸,价值约771,679,000美元。ClearBridge Investments LLC在第一季度将其在Certara股票的头寸增加了58.7%。ClearBridge Investments LLC现在拥有该公司3,200,895股股票,价值68,755,000美元,在此期间又购买了1,183,859股。威廉·布莱尔投资管理公司在第四季度将其在Certara股票的头寸增加了23.0%。威廉·布莱尔投资管理公司在此期间又购买了1,034,482股,现在拥有5,540,678股该公司股票,价值157,466,000美元。Granite Investment Partners LLC在第二季度收购了Certara的一个新头寸,价值约为18,944,000美元。最后,Capital World Investors在第四季度增持了Certara的股份215.5%。Capital World Investors现在持有该公司1,254,554股股票,价值35,654,000美元,在此期间又购买了856,959股。77.42%的股份由机构投资者持有。

About Certara

关于Certara

(Get Rating)

(获取评级)

Certara, Inc provides software products and technology-enabled services to customers for biosimulation in drug discovery, preclinical and clinical research, regulatory submissions, and market access. It offers medicines to patients using biosimulation software, technology, and services to transform drug discovery and development.

Certara公司为客户提供软件产品和技术支持的服务,用于药物发现、临床前和临床研究、监管提交和市场准入方面的生物模拟。它使用生物模拟软件、技术和服务向患者提供药物,以改变药物发现和开发。

Further Reading

进一步阅读

  • Get a free copy of the StockNews.com research report on Certara (CERT)
  • MarketBeat: Week in Review 9/5 – 9/9
  • Prepare For A Record-Setting Quarter For Cyber Security Stocks
  • The Auto Market Is Slowly Recovering, These Stocks May Outperform
  • Is DocuSign On The Verge Of A Major Reversal?
  • Oil and Gas Stocks: A Safe Way to Invest in Renewable Energy
  • 免费获取StockNews.com关于Certara的研究报告(CERT)
  • MarketBeat:回顾一周9/5-9/9
  • 为网络安全股创纪录的季度做准备
  • 汽车市场正在缓慢复苏,这些股票可能表现优异
  • DocuSign是否即将发生重大逆转?
  • 石油和天然气股票:投资可再生能源的安全途径

Receive News & Ratings for Certara Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Certara and related companies with MarketBeat.com's FREE daily email newsletter.

接受Certara日报的新闻和评级-在下面输入您的电子邮件地址,通过MarketBeat.com的免费每日电子邮件时事通讯接收对Certara和相关公司的最新新闻和分析师评级的每日简要摘要。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发